9.22
0.01 (0.11%)
| 前收盘价格 | 9.21 |
| 收盘价格 | 9.24 |
| 成交量 | 599,140 |
| 平均成交量 (3个月) | 1,088,795 |
| 市值 | 841,869,952 |
| 预期市盈率 (P/E Forward) | 125.00 |
| 价格/销量 (P/S) | 1.05 |
| 股市价格/股市净资产 (P/B) | 1.27 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -15.20% |
| 营业利益率 (TTM) | -8.22% |
| 稀释每股收益 (EPS TTM) | -1.41 |
| 季度收入增长率 (YOY) | 7.10% |
| 总债务/股东权益 (D/E MRQ) | 20.01% |
| 流动比率 (MRQ) | 1.82 |
| 营业现金流 (OCF TTM) | -8.70 M |
| 杠杆自由现金流 (LFCF TTM) | 13.25 M |
| 资产报酬率 (ROA TTM) | -5.06% |
| 股东权益报酬率 (ROE TTM) | -17.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Myriad Genetics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | -3.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.50 |
|
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.17% |
| 机构持股比例 | 104.02% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Glenview Capital Management, Llc | 31 Dec 2024 | 4,157,324 |
| Camber Capital Management Lp | 31 Dec 2024 | 3,100,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 29.00 (Craig-Hallum, 214.53%) | 购买 |
| 中 | 18.50 (100.65%) | |
| 低 | 11.00 (B of A Securities, 19.31%) | 卖出 |
| 平均值 | 18.19 (97.29%) | |
| 总计 | 5 购买, 2 保留, 1 卖出 | |
| 平均价格@调整类型 | 11.45 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Scotiabank | 01 Apr 2025 | 20.00 (116.92%) | 购买 | 9.22 |
| Piper Sandler | 12 Mar 2025 | 12.50 (35.57%) | 购买 | 10.41 |
| 04 Mar 2025 | 11.50 (24.73%) | 保留 | 10.42 | |
| B of A Securities | 03 Mar 2025 | 11.00 (19.31%) | 卖出 | 10.39 |
| Raymond James | 25 Feb 2025 | 19.00 (106.07%) | 购买 | 11.74 |
| UBS | 25 Feb 2025 | 16.00 (73.54%) | 保留 | 11.74 |
| Craig-Hallum | 12 Feb 2025 | 29.00 (214.53%) | 购买 | 13.09 |
| Goldman Sachs | 28 Jan 2025 | 18.00 (95.23%) | 购买 | 12.50 |
| Stephens & Co. | 16 Jan 2025 | 20.00 (116.92%) | 保留 | 12.52 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ANCONA MARGARET | - | 10.01 | -2,622 | -26,246 |
| DIAZ PAUL J | - | 10.00 | -117,680 | -1,176,623 |
| HAAS KEVIN RICHARD | - | 10.00 | -9,088 | -90,884 |
| MUNK NATALIE | - | 10.00 | -2,545 | -25,446 |
| MUZZEY DALE | - | 10.00 | -8,690 | -86,947 |
| VERRATTI MARK | - | 10.00 | -7,690 | -76,896 |
| 累积净数量 | -148,315 | |||
| 累积净值 ($) | -1,483,041 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 10.00 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DIAZ PAUL J | 职员 | 24 Mar 2025 | 处理 (-) | 45,139 | 9.98 | 450,487 |
| VERRATTI MARK | 职员 | 24 Mar 2025 | 处理 (-) | 2,701 | 9.98 | 26,956 |
| MUZZEY DALE | 职员 | 24 Mar 2025 | 处理 (-) | 1,345 | 9.98 | 13,423 |
| HAAS KEVIN RICHARD | 职员 | 24 Mar 2025 | 处理 (-) | 2,901 | 9.98 | 28,952 |
| MUNK NATALIE | 职员 | 24 Mar 2025 | 处理 (-) | 982 | 9.98 | 9,800 |
| DIAZ PAUL J | 职员 | 22 Mar 2025 | 处理 (-) | 72,541 | 10.01 | 726,135 |
| VERRATTI MARK | 职员 | 22 Mar 2025 | 处理 (-) | 4,989 | 10.01 | 49,940 |
| MUZZEY DALE | 职员 | 22 Mar 2025 | 处理 (-) | 7,345 | 10.01 | 73,523 |
| HAAS KEVIN RICHARD | 职员 | 22 Mar 2025 | 处理 (-) | 6,187 | 10.01 | 61,932 |
| MUNK NATALIE | 职员 | 22 Mar 2025 | 处理 (-) | 1,563 | 10.01 | 15,646 |
| ANCONA MARGARET | 职员 | 22 Mar 2025 | 处理 (-) | 2,622 | 10.01 | 26,246 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合